Zobrazeno 1 - 10 of 50 pro vyhledávání: '"Luke Godwin"'
1
Akademický článek
Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
Autor: James Luke Godwin, Shuchie Jaggi, Imali Sirisena, Pankaj Sharda, Ajay D. Rao, Ranee Mehra, Colleen Veloski
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-7 (2017)
Abstract Background Advances in cancer immunotherapy have generated encouraging results in multiple malignancies refractory to standard chemotherapies. As the use of immune checkpoint inhibitors (ICI) proliferates, the incidence of autoimmune side ef
Externí odkaz: https://doaj.org/article/1792c8ef251c4c0f95acdbb90376aa97
Zobrazit plný text záznamu
4
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Autor: Peter H. O'Donnell, Petros Grivas, Blanca Homet Moreno, Joaquim Bellmunt, Elizabeth R. Plimack, Mary J. Savage, Daniel Castellano, Xiao Fang, Dean F. Bajorin, Ronald de Wit, Thomas Powles, Tara L. Frenkl, Arjun Vasant Balar, Jacqueline Vuky, Noah M. Hahn, James Luke Godwin
Publikováno v: Journal of Clinical Oncology, 38(23), 2658-+. American Society of Clinical Oncology
PURPOSE The phase II single-arm KEYNOTE-052 study evaluated the efficacy and safety of first-line pembrolizumab for patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma (UC). PATIENTS AND METHODS Three hundred sevent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7dc84f018142d34aefa6e59f423c85a
https://doi.org/10.1200/jco.19.01213
Zobrazit plný text záznamu
5
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Autor: James Luke Godwin, Dean F. Bajorin, Joaquim Bellmunt, Petros Grivas, Tara L. Frenkl, Thomas Powles, Misoo C. Ellison, Arjun Vasant Balar, Jacqueline Vuky, Daniel Castellano, Ronald de Wit, Noah M. Hahn, Elizabeth R. Plimack, Peter H. O'Donnell
Publikováno v: European urology oncology
European urology oncology, 3(3), 351-359. Elsevier
Background: Patients with treatment-naive advanced urothelial cancer (UC) Ineligible for cisplatin-based chemotherapy are typically older and have comorbidities, representing a difficult-to-treat population. Objective: To evaluate the safety and anti
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab1c661cea767882d1d3eb214810c31e
https://doi.org/10.1016/j.euo.2020.02.009
Zobrazit plný text záznamu
6
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Autor: Joaquim Bellmunt, Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae-Lyun Lee, Lawrence Fong, Andrea Necchi, Cora N. Sternberg, Peter H. O'Donnell, Thomas Powles, Elizabeth R. Plimack, Dean F. Bajorin, Arjun V. Balar, Daniel Castellano, Toni K. Choueiri, Stephane Culine, Winald Gerritsen, Howard Gurney, David I. Quinn, Jacqueline Vuky, Nicholas J. Vogelzang, Razvan Cristescu, Jared Lunceford, Assieh Saadatpour, Andrey Loboda, Junshui Ma, Mohini Rajasagi, James Luke Godwin, Blanca Homet Moreno, Petros Grivas
Publikováno v: Clinical Cancer Research, 28, 10, pp. 2050-2060
Clinical Cancer Research, 28(10), 2050-2060. American Association for Cancer Research Inc.
Clinical Cancer Research, 28, 2050-2060
Purpose: In an exploratory analysis, we investigated the association between programmed death ligand 1 (PD-L1), tumor mutational burden (TMB), T-cell–inflamed gene expression profile (TcellinfGEP), and stromal signature with outcomes of pembrolizum
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9a033eea1a8dbe8ea54e8402e4eed44
https://repository.ubn.ru.nl/handle/2066/250670
Zobrazit plný text záznamu
7
Akademický článek
Muscle-invasive urothelial bladder cancer: an update on systemic therapy
Autor: Hayley Knollman, J. Luke Godwin, Rishi Jain, Yu-Ning Wong, Elizabeth R. Plimack, Daniel M. Geynisman
Publikováno v: Therapeutic Advances in Urology, Vol 7 (2015)
Urothelial carcinoma is a common malignancy that carries a poor prognosis when the disease includes muscle invasion. Metastatic urothelial carcinoma is almost uniformly fatal. The evidence behind treatment options in the neoadjuvant, adjuvant and met
Externí odkaz: https://doaj.org/article/87461be9963a4b9e94257975c4368ce6
Zobrazit plný text záznamu
8
Ossifying Fibromyxoid Tumor: A Rare Subcutaneous Tumor
Autor: David Rowe, Chad Johnston, Karla C. Guerra, Luke Godwin, Maggie Noland
Publikováno v: HCA Healthc J Med
Description The following case study demonstrates a 26-year-old male that presented to the dermatology clinic with an enlarging, raised skin nodule located on the left inferior lateral lower back. The patient reported it had persisted for two years,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a106df9b3c0d6e58439676707d60f14f
https://doi.org/10.36518/2689-0216.1288
Zobrazit plný text záznamu
9
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States
Autor: Karl Patterson, Oliver Hale, Blanca Homet Moreno, Yang Meng, Yizhen Lai, Haojie Li, Ronac Mamtani, James Luke Godwin
Publikováno v: Clinical genitourinary cancer. 19(1)
Introduction Pembrolizumab has been approved in the United States (US) for the first-line treatment of patients with advanced or metastatic urothelial carcinoma, who are ineligible for cisplatin-containing chemotherapy and with tumors expressing prog
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9283c21d50efa1fd469647775a0df306
https://pubmed.ncbi.nlm.nih.gov/32826180
Zobrazit plný text záznamu
10
The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States
Autor: Yizhen Lai, James Luke Godwin, Ronac Mamtani, Guru Sonpavde, Blanca Homet Moreno, Yichen Zhong, Yang Meng, Haojie Li, Rachael Louise Slater, Tara L. Frenkl
Aims: Pembrolizumab demonstrated significantly prolonged overall survival (OS) vs. chemotherapy in the Phase III KEYNOTE-045 trial, and is approved in the US for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cd0206a4ee4acfdbfd8aa37a6ed4b1c
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje